NYSE$WST
West Pharmaceutical Services Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Announced second-quarter 2020 financial results, reflecting business strength and resilience.
West Pharmaceutical Services reported a 12.2% increase in net sales to $527.2 million and a 40% increase in adjusted-diluted EPS to $1.25 for the second quarter of 2020. The company is raising full-year 2020 net sales guidance to between $2.035 billion and $2.055 billion, and adjusted-diluted EPS guidance to between $4.15 and $4.25.
- Net sales grew by 12.2% to $527.2 million, with organic sales growth of 14.3%.
- Reported-diluted EPS increased by 38% to $1.21.
- Adjusted-diluted EPS increased by 40% to $1.25.
- Full-year 2020 net sales guidance raised to a new range of between $2.035 billion and $2.055 billion.
Headline financials
Revenue & EPS history
West Pharma · Revenue · Quarterly
$527M
Revenue by segment
West Pharma · $527M total across 2 segments · Q2 2020
- Proprietary Products$400M+10.9%75.8%
- Contract-Manufactured Products$128M+16.8%24.2%
Forward guidance
Full-year 2020 net sales are expected to be in a range of between $2.035 billion and $2.055 billion. Organic sales growth is expected to be approximately 12%. Full-year 2020 adjusted-diluted EPS is expected to be in a range of between $4.15 and $4.25.
Tailwinds
- Full-year 2020 net sales guidance is expected to be in a range of between $2.035 billion and $2.055 billion.
- Organic sales growth is expected to be approximately 12%.
- Net sales guidance includes an estimated full-year headwind of $26 million for the full-year 2020 based on current foreign exchange rates.
- Full-year 2020 adjusted-diluted EPS is expected to be in a range of between $4.15 and $4.25.
- Full-year adjusted-diluted EPS guidance includes an estimated headwind of approximately $0.07 based on current foreign currency exchange rates.
Headwinds
- The revised guidance includes a $0.16 EPS impact from tax benefits from stock-based compensation in the first six months of 2020.
- For the remainder of the year, our EPS guidance range assumes a tax rate of 24% and does not include potential tax benefits from stock-based compensation.
- Any tax benefits associated with stock-based compensation beyond those recorded in the first six months of 2020 would provide a positive adjustment to our full-year EPS guidance.
- The duration and severity of the global COVID-19 pandemic, including prevailing economic conditions and general uncertainties relating thereto that may be unknown and unforeseeable
- Customers’ changing inventory requirements and manufacturing plans and customer decisions to move forward with our new products and product categories, including any re-prioritization of product needs due to COVID-19
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+0.0%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.9%
Avg return
30 days after
51%
35 / 69 earnings
Positive
+14.9%
Q1 2020
Best reaction
-38.2%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.3% | +6.5% | +15.4% | |
| Q4 2025 | -1.0% | -1.2% | -4.3% | |
| Q3 2025 | +11.1% | +2.3% | -2.1% | |
| Q2 2025 | -0.0% | +0.3% | +3.0% | |
| Q1 2025 | -3.5% | -2.2% | -5.8% | |
| Q4 2024 | -38.2% | -34.5% | -28.6% | |
| Q3 2024 | +7.5% | +11.2% | +10.5% | |
| Q2 2024 | -12.0% | -7.5% | -6.5% | |
| Q1 2024 | -6.6% | -7.3% | -14.0% | |
| Q4 2023 | -11.3% | -14.2% | -5.0% | |
| Q3 2023 | -10.4% | -11.1% | -1.3% | |
| Q2 2023 | -3.7% | -2.0% | +3.8% | |
| Q1 2023 | +1.1% | +3.5% | -3.8% | |
| Q4 2022 | +12.4% | +9.9% | +18.1% | |
| Q3 2022 | -11.4% | -9.8% | -10.9% | |
| Q2 2022 | +7.2% | +5.8% | -5.2% | |
| Q1 2022 | -5.2% | -7.8% | -3.4% | |
| Q4 2021 | -2.6% | -2.7% | +9.3% | |
| Q3 2021 | +2.0% | +4.0% | +4.2% | |
| Q2 2021 | +7.2% | +9.9% | +16.4% | |
| Q1 2021 | +2.0% | +2.2% | +7.8% | |
| Q4 2020 | -4.2% | -6.7% | -5.7% | |
| Q3 2020 | -0.9% | +0.6% | +0.1% | |
| Q2 2020 | +2.9% | +3.5% | +6.3% | |
| Q1 2020 | +14.9% | +13.5% | +24.3% | |
| Q4 2019 | +7.6% | +6.8% | -9.9% | |
| Q3 2019 | +1.2% | +3.1% | +5.2% | |
| Q2 2019 | +12.0% | +12.4% | +17.2% | |
| Q1 2019 | +7.4% | +7.4% | +0.9% | |
| Q4 2018 | -3.7% | -4.0% | -2.0% | |
| Q3 2018 | -9.6% | -6.4% | -5.5% | |
| Q2 2018 | +10.0% | +10.0% | +17.2% | |
| Q1 2018 | +1.0% | -0.3% | +4.0% | |
| Q4 2017 | -8.0% | -5.7% | -4.3% | |
| Q3 2017 | +10.4% | +10.6% | +6.3% | |
| Q2 2017 | -3.4% | -5.3% | -7.8% | |
| Q1 2017 | +9.6% | +12.2% | +15.5% | |
| Q4 2016 | -4.4% | -4.0% | -4.9% | |
| Q3 2016 | +3.9% | +5.2% | +16.3% | |
| Q2 2016 | +2.4% | +3.0% | +4.0% | |
| Q1 2016 | -1.2% | — | — | |
| Q4 2015 | +4.1% | — | — | |
| Q3 2015 | +0.1% | — | — | |
| Q2 2015 | -1.2% | — | — | |
| Q1 2015 | -3.1% | — | — | |
| Q4 2014 | +2.7% | — | — | |
| Q3 2014 | +8.3% | — | — | |
| Q2 2014 | -0.1% | — | — | |
| Q1 2014 | +0.5% | — | — | |
| Q4 2013 | +0.8% | — | — | |
| Q3 2013 | +0.6% | — | — | |
| Q2 2013 | +3.4% | — | — | |
| Q1 2013 | +1.2% | — | — | |
| Q4 2012 | +3.3% | — | — | |
| Q3 2012 | -2.3% | — | — | |
| Q2 2012 | +2.6% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q4 2011 | -2.1% | — | — | |
| Q3 2011 | +2.2% | — | — | |
| Q2 2011 | +2.1% | — | — | |
| Q1 2010 | -0.6% | — | — | |
| Q1 2011 | +1.4% | — | — | |
| Q4 2008 | -1.9% | — | — | |
| Q4 2010 | -1.9% | — | — | |
| Q3 2010 | -0.7% | — | — | |
| Q3 2009 | -0.7% | — | — | |
| Q2 2009 | -2.4% | — | — | |
| Q4 2009 | -2.4% | — | — | |
| Q2 2010 | -2.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro